ANIX — ANIXA BIOSCIENCES INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ANIXA BIOSCIENCES INC (ANIX)
ANIXA BIOSCIENCES INC (ANIX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $316,833. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ANIX
How many top investors track ANIX
A small number of top investors own this.
ANIX Ownership Composition
How ANIXA BIOSCIENCES INC is held across tracked investor types, based on reported 13F positions.
- Other67.4%
- Hedge Funds32.6%
Tracked investors reporting ANIX
- Ken GriffinMar 31, 2026Citadel AdvisorsShares21KValue$54.2K% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares17.3KValue$44.6K% Portfolio0.00%
- Izzy EnglanderDec 31, 2025Millennium ManagementShares12.2KValue$38K% Portfolio0.00%
Recent activity
- $38KFeb 17, 2026
- New$96.9KFeb 17, 2026
- New$54.2KMay 15, 2026
- New$44.6KMay 15, 2026
- New$316.8KNov 14, 2025
Frequently asked questions
- How many institutional investors hold ANIX?
- 3 tracked institutional investors disclosed a position in ANIX (ANIXA BIOSCIENCES INC) in their most recent 13F filing.
- Who is the largest institutional holder of ANIX?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ANIX, valued at $316,833.
- Did institutional ownership of ANIX increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited ANIX.
- Where does this ANIX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.